The US Food and Drug Administration (FDA) has approved osimertinib (Tagrisso, AstraZeneca Pharmaceuticals) for the treatment ...

Tagrisso, which targets exon 19 deletions or exon 21 (L858R) mutations, received the approval following a priority review.

The Zacks Daily presents the best research output of our analyst team. Today's Daily features new research reports on 16 ...

In several short films directed by Reed Morano, the “What science can do” campaign features stories from a cancer patient and an asthma patient.

AstraZeneca will pay $18 million to biotechnology firm Immunai Inc to use the New York-based firm's AI model of the immune ...

AstraZeneca and Daiichi Sankyo's Dato-DXd failed to improve survival in a breast cancer study. Gilead Sciences' Kite will bow ...

According to GlobalData, the US vaccination rate for seasonal influenza during the 2023-2024 season was estimated to be 47%, ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Toyota Motor Corp. (TM), AstraZeneca ...

While there are a few different strategies to build wealth through the stock market, this Footsie ETF may be the most ...

Sanofi’s Dupixent has been cleared for a chronic lung disorder in the US, in another milestone for the blockbuster drug after ...

After more than a decade without any therapeutic advancements in chronic obstructive pulmonary disorder (COPD), people with ...